Will Extend Period Of Reduction In Executive Remuneration As Co Continues To Face Challenging Business Situation
April 4 (Reuters) - Sumitomo Pharma Co Ltd 4506.T: SUMITOMO PHARMA CO - WILL EXTEND PERIOD OF REDUCTION IN EXECUTIVE REMUNERATION AS CO CONTINUES TO FACE CHALLENGING BUSINESS SITUATION SUMITOMO PHARMA CO - CEO'S BASE REMUNERATION TO BE REDUCED 30% FROM APRIL TO JUNE Source text: ID:nTSpd7c4af Further company coverage: 4506.T
Recent news on Sumitomo Pharma
See all newsSumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa
Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)
Brief: Sumitomo Pharma - Gotham City Research's August 3 Report Contains Numerous Statements That Are Clearly Inconsistent With Facts
Brief: Gotham City Research Holds Short Positions In Sumitomo Chemical And Sumitomo Pharmaceutical
Table: Sumitomo Pharma -Q1 group results (IFRS)